Back
Compare AU
Compare DTEC vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X Defence Tech ETF (DTEC) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DTEC | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 159 | 67 |
Median incremental investment | $1,000.00 | $665.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,833.00 | $1,882.88 |
Average age group | > 35 | > 35 |
Key Summary
DTEC | CURE | |
|---|---|---|
Strategy | DTEC.AX was created on 2024-10-07 by Global X. The fund's investment portfolio concentrates primarily on industrials equity. The investment objective of the Fund is to provide investors with a return that (before fees and expenses) tracks the performance of the Global X Defense Tech Index. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 40.41m in AUM and 144 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Lockheed Martin Corp (9.28 %) RTX Corp (7.77 %) General Dynamics Corp (7.07 %) | Moderna Inc (2.14 %) Roivant Sciences Ltd Ordinary Shares (1.69 %) Vaxcyte Inc Ordinary Shares (1.66 %) |
Top 3 industries | Industrials (84.07 %) Information Technology (15.93 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (59.63 %) Germany (8.21 %) Korea (6.97 %) | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) |
Management fee | 0.51 % | 0.45 % |
Key Summary
DTEC | CURE | |
|---|---|---|
Issuer | Global X | Global X |
Tracking index | Global X Defense Tech Index - Benchmark TR Net | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.51 % | 0.45 % |
Price | $19.50 | $58.84 |
Size | $139.112 million | $40.284 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 0.09 % | 5.08 % |
Market | ASX | ASX |
First listed date | 08/10/2024 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DTEC | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 159 | 67 |
Median incremental investment | $1,000.00 | $665.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,833.00 | $1,882.88 |
Average age group | > 35 | > 35 |
Pros and Cons
DTEC | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DTEC | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |